Bristol-Myers Squibb Co. vs Abbvie Inc.
BMY vs ABBV — side-by-side comparison from reported financials. BMY leads 7, ABBV leads 5 of 12 comparable metrics.
Bristol-Myers Squibb Co.
BMY · Healthcare
$59.14-0.75%Solid
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | BMY | ABBV |
|---|---|---|
| Price | $59.14 | $276.43 |
| Market cap | $121B | $488B |
| Revenue (TTM) | $49.2B | $64.4B |
| Revenue growth | +1.4% | +1.8% |
| Net margin | 18.9% | 9.8% |
| Free cash flow | $11.4B | $18.2B |
| Net cash (debt) | ($34.4B) | ($56.2B) |
| 1-year price return | +32.4% | +19.8% |
| P/E | 13.0 | 77.4 |
| P/E vs own history (cheap-side %) | 90% | 23% |
| Dividend yield | 6.28% | 2.45% |
| Return on equity | 47% | 96% |
| Altman Z-score | 2.16 | 2.33 |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 32,500 | 57,000 |
Full résumé-style profiles: BMY CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.